Perioperative NOAC Management
Definition
Perioperative management of NOACs involves timing of preoperative interruption based on bleeding risk, renal function (which determines drug clearance), and drug-specific pharmacokinetics. The central principle established by the 2018 EHRA Practical Guide: no bridging with LMWH or UFH — the predictable waning of NOAC effect makes bridging unnecessary, and bridging increases bleeding without reducing thromboembolic events. The PAUSE trial subsequently confirmed this framework.
Key Concepts
General Principles
- No bridging with LMWH/UFH for NOAC-treated patients undergoing planned procedures — the short, predictable half-life of NOACs renders bridging unnecessary and harmful (bridges the only period of non-anticoagulation with an additional anticoagulant) (sources/noac-ehra-2018, rating: high)
- BRIDGE trial (VKA patients): bridging associated with significantly higher major bleeding without reducing cardiovascular events — same logic applied to NOACs (sources/noac-ehra-2018, rating: high)
- Patients taking concomitant verapamil, dronedarone, or amiodarone may need an additional 24h interruption beyond standard timing (drug-drug interaction increases NOAC levels)
- Renal function (CrCl) is the key variable — dabigatran (80% renal) is most sensitive; FXa inhibitors less affected
Low Bleeding Risk Procedures
Examples: dental extraction, superficial surgery, cataract/glaucoma surgery, endoscopy without biopsy, pacemaker/ICD implantation, joint aspiration, peripheral nerve blocks
Timing of last NOAC dose:
| Procedure risk | Dabigatran | FXa Inhibitors (apixaban, rivaroxaban, edoxaban) |
|---|---|---|
| Low risk, CrCl ≥80 | ≥24h before | ≥24h before |
| Low risk, CrCl 50–79 | ≥36h before | ≥24h before |
| Low risk, CrCl 30–49 | ≥48h before | ≥24h before |
| Low risk, CrCl 15–29 | Not indicated | ≥36h before |
| (sources/noac-ehra-2018, rating: high) |
Resume: ≥24h after procedure (when hemostasis is achieved)
High Bleeding Risk Procedures
Examples: major surgery (cardiac, aortic, thoracic, abdominal), spinal surgery, urological surgery, neurosurgery, joint replacement, coronary bypass
Timing of last NOAC dose:
| Procedure risk | Dabigatran | FXa Inhibitors |
|---|---|---|
| High risk, CrCl ≥80 | ≥48h before | ≥48h before |
| High risk, CrCl 50–79 | ≥72h before | ≥48h before |
| High risk, CrCl 30–49 | ≥96h before | ≥48h before |
| High risk, CrCl 15–29 | Not indicated | ≥48h before |
| (sources/noac-ehra-2018, rating: high) |
Resume: 48–72h after procedure
Specific Procedure Types
Dental surgery:
- Generally no NOAC interruption needed
- Local hemostasis: oxidized cellulose, absorbable gelatin, sutures, tranexamic acid mouthwash
- Avoid NSAIDs for analgesia (sources/noac-ehra-2018, rating: high)
Cardiac device implantation (BRUISE-CONTROL 2 data):
- Last NOAC dose: morning of day before procedure
- Restart: the following day
- Both interrupted and continued strategies had similar bleeding and embolic rates for FXa inhibitors; dabigatran follow CrCl-based timing (sources/noac-ehra-2018, rating: high)
Neuraxial (spinal/epidural) anaesthesia and lumbar puncture:
- High-risk category — full haemostatic function required
- Interrupt: ≥3 days (5 half-lives) for FXa inhibitors; ≥4–5 days for dabigatran
- Resume: 24h after intervention (≥6h for peripheral nerve blocks)
- If neuraxial must proceed and no specific reversal agent available: prefer general anaesthesia to reduce epidural haematoma risk (sources/noac-ehra-2018, rating: high)
AF catheter ablation:
- Two acceptable strategies: (1) truly uninterrupted NOAC; (2) last dose 12h before procedure
- Choice based on: CrCl, CHA₂DS₂-VASc, trans-septal puncture approach, operator experience
- If last dose >36h before: rule out LAA thrombus with TOE prior to ablation
- During ablation: IV heparin to ACT 300–350s; same target as VKA-treated patients
- Resume: 3–5h after sheath removal if hemostasis adequate and pericardial effusion excluded (sources/noac-ehra-2018, rating: high)
Coronary angiography/PCI (elective):
- Stop NOAC ≥12–24h before
- Periprocedural: UFH 70IU/kg or bivalirudin (preferred over enoxaparin)
- Restart NOAC after parenteral anticoagulation discontinued; avoid switching to VKA post-PCI (sources/noac-ehra-2018, rating: high)
Urgent and Emergency Surgery
Three urgency tiers with escalating use of reversal agents:
Immediate (life/limb-threatening, minutes):
- Operate without delay
- Specific reversal if available: idarucizumab (dabigatran), andexanet alfa (FXa inhibitors)
- If no specific reversal: (a)PCC
- Prefer general over spinal anaesthesia if no reversal agent
- Full coagulation panel (PT, aPTT, anti-FXa or dTT/ECA) to guide further management (sources/noac-ehra-2018, rating: high)
Urgent (hours):
- Defer ≥12h (ideally 24h) if clinically possible
- Await coagulation test results
- (a)PCC if NOAC levels significantly elevated and reversal needed (sources/noac-ehra-2018, rating: high)
Expedite (days):
- Follow elective interruption rules (standard timing table above) (sources/noac-ehra-2018, rating: high)
Coagulation Test Guidance for Urgent Surgery
- Normal aPTT (dabigatran): excludes high plasma levels (but not 'on-therapy' levels)
- Normal PT (rivaroxaban/edoxaban): may exclude high plasma levels
- Specific assays: dTT/ECA for dabigatran; anti-FXa chromogenic assay for FXa inhibitors — preferred for urgent decisions
- No prospectively validated cut-off levels to define 'safe' NOAC level for surgery — threshold guidance is expert opinion (sources/noac-ehra-2018, rating: high)
Contradictions / Open Questions
- PAUSE trial (NCT02228798): referenced as ongoing in 2018 guide; subsequently published (2019) — confirmed simplified standardized interruption without bridging for AF patients on NOACs undergoing elective procedures: 30-day major bleeding 1.35% (apixaban), 0.90% (dabigatran), 1.85% (rivaroxaban); arterial thromboembolism <1% in all groups
- Optimal resumption timing: the 24h/48-72h thresholds are expert consensus without hard clinical outcome data; hemostasis confirmation is the practical guide
- NOAC level thresholds for safe surgery: no validated clinical cut-off values; expert consensus only; PAUSE trial attempted to define this for standard patients but complex cases remain uncertain
- Ablation anticoagulation strategy: RE-CIRCUIT and AXAFA-AFNET trials (uninterrupted dabigatran and apixaban) published 2017-2018 support uninterrupted strategy but were not incorporated in the 2018 guide
Connections
- Related to concepts/NOAC-AF-Management — overall NOAC framework
- Related to concepts/AF-Stable-CAD-Antithrombotic — periprocedural in ACS/PCI context
- Related to concepts/Catheter-Ablation-AF — ablation-specific periprocedural anticoagulation
Sources
- sources/noac-ehra-2018 — primary source (Topics 12–13)